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Abstract
An estimated one-third of individuals positive for HIV
are also infected with hepatitis C virus (HCV). Chronic
infection with HCV can lead to serious liver disease
including cirrhosis and hepatocellular carcinoma.
Liver-related disease is among the leading causes of
death in patients with HIV, and individuals with HIV
and HCV co-infection are found to progress more
rapidly to serious liver disease than mono-infected
individuals. The mechanism by which HIV affects HCV
infection in the absence of immunosuppression by
HIV is currently unknown. In a recent article published
in BMC Immunology,Q uet al. demonstrated that HIV
tat is capable of inducing IP-10 expression. Further,
they were able to show that HIV tat, when added to
cells, was able to enhance the replication of HCV.
Importantly, the increase in HCV replication by tat was
found to be dependent on IP-10. This work has
important implications for understanding the effect
HIV has on the outcome of HCV infection in co-
infected individuals. The findings of Qu et al. may
inform the design of intervention and treatment
strategies for co-infected individuals.
Please see related article: http://www.biomedcentral.
com/1471-2172/13/15.
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Background
A significant number of individuals with HIV are co-
infected with serious human pathogens such as hepatitis
C virus (HCV), which infects up to 170 million people
globally [1]. Due to similar routes of infection for HIV
and HCV, it is estimated that up to a third of people
with HIV are co-infected with HCV [1-3]. With an esti-
mated 34 million cases of HIV infection worldwide [4],
this represents a disease burden for individuals with co-
infection of HIV and HCV of greater than 10 million
people. Prior to the era of effective anti-retroviral ther-
apy, patients with HIV did not live long enough to suf-
fer disease caused by chronic infection with HCV.
However, as a result of the effectiveness of current anti-
retroviral therapies, these individuals with HIV and
HCV co-infection are now living long enough to be
affected by disease caused by chronic HCV infection.
Liver-related disease is a leading cause of death in
individuals infected with HIV, mostly due to co-infec-
tion with HCV [1,5,6]. There is an abundance of evi-
dence that the normal progression of HCV pathogenesis
is altered in the presence of HIV [7-10]. These studies
have shown that individuals co-infected with HIV and
HCV possess higher levels of HCV RNA, and progress
more rapidly to serious liver disease, including cirrhosis
and hepatocellular carcinoma [11]. Individuals with an
HIV and HCV co-infection are also more resistant to
standard HCV treatments than patients with an HCV
mono-infection. For example, successful treatment with
interferon/ribavirin in patients with an HCV genotype 1
mono-infection reaches 50% to 80% while in co-infected
individuals effective treatment is reduced to 20% to 35%
[1]. The mechanisms by which HIV affects HCV infec-
tion in individuals with a co-infection are currently
unknown.
IP-10 and HIV and HCV co-infection
A number of research groups have sought to determine
how HIV infection affects HCV in individuals that are
co-infected. Multiple studies have identified elevated IP-
10 (CXCL10) levels as a negative prognostic indicator
for both HCV infection and HIV and HCV co-infection
[12-14]. Further, elevated IP-10 levels were associated
with the poor response to interferon/ribavirin therapy
noted above [15]. IP-10 is a CXC chemokine that binds
to the CXCR3 immune system receptor present on a
number of cells, including monocytes, natural killer cells
and T-cells [16]. Binding of IP-10 to CXCR3 induces
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injury. It is thought that elevated IP-10 could recruit T-
cells from the periphery and within the liver, mediating
the damage seen in cirrhosis and hepatocellular carci-
noma [17]. The mechanism by which elevated levels of
IP-10 may affect HCV infection in individuals with HIV
and HCV co-infection is not known.
Work by Qu et al., published in BMC Immunology,
describes a potential molecular mechanism for the influ-
ence HIV has on HCV infection in individuals with HIV
and HCV co-infection. Specifically, Qu et al. present
findings describing a potential cause-and-effect relation-
ship between HIV infection and increased HCV replica-
tion. HIV tat is shown to increase levels of IP-10 mRNA
and protein and consequently enhance HCV replication.
Importantly, IP-10 induction by tat is shown to be
necessary and sufficient to increase HCV replication
levels. Their data further demonstrate a synergism in
the ability of HIV and HCV to induce IP-10: hepato-
cytes that were both infected with HCV and treated
with HIV tat induced higher levels of IP-10 mRNA and
p r o t e i nt h a ne i t h e rH C Vi n f e c t i o no rt r e a t m e n tw i t h
HIV tat alone.
Understanding co-infection
It is challenging for many to imagine a situation in
which both HIV and HCV would find themselves in the
same cell and thus in a position to affect the replication
of one another. However, specialized immune cells,
called peripheral blood mononuclear cells and Kupffer
cells, are sites of infection for both HIV and HCV and
the possibility exists that both HIV and HCV could find
themselves in the same cell in an individual with a co-
infection [18]. Experiments should be carried out to
determine if tat-induced IP-10 can affect HCV replica-
tion in Kupffer cells and peripheral blood mononuclear
cells. However, an interesting implication of the work
presented by Qu et al. is that HIV does not need to be
present in the same cell to exert an effect on HCV
infection. Both tat [19] and IP-10 can act on cells dis-
tant from the site of HIV infection.
T h ew o r kb yQ uet al. poses many intriguing and
important questions. Certainly it is important to deter-
mine the mechanisms by which HIV upregulates IP-10
expression and, more importantly, how IP-10 enhances
HCV replication. CXCR3 receptor expression is not
known to be expressed on hepatocytes [16]; thus, in the
experiments described by Qu et al., IP-10 may be acting
through an as yet unknown mechanism. Additionally, it
was recently shown that induced IP-10 in patients with
HCV infection was expressed in a truncated, antagonist
form [20]. Cellular proteinases responsible for the con-
version of IP-10 to its antagonist form are presumably
absent in the experiments performed by Qu et al. It will
be interesting to determine which form is important in
individuals who are co-infected and whether the antago-
nistic IP-10 has a similar influence on HCV replication
as found in the paper.
There are reports of a genotype-specific response to
HCV treatments [15] and it will be necessary to deter-
mine whether IP-10’s effect on HCV is genotype speci-
fic. Similar experiments will need to be performed using
multiple genotypes. Further, these findings will need to
be addressed in an in vivo setting, such as a humanized
mouse or primate model, to assess the relevance of
these findings to the pathogenesis of HIV and HCV co-
infection. IP-10 is the only chemokine examined by Qu
et al.;h o w e v e r ,m u l t i p l ec h e m o k i n e sa r ef o u n dt ob e
differentially regulated in individuals with HCV-asso-
ciated liver disease [17]. It will be important to deter-
mine if other chemokines are able to enhance HCV
replication as shown in the paper by Qu et al.
An important consideration for HIV co-infection stu-
dies is whether the effect measured is due to HIV or
whether the effect can be attributed to the immunodefi-
ciency that defines AIDS [1]. The relationship between
HIV and pathogens such as HCV in individuals with a
co-infection is not simply one of opportunism, whereby
the immunodeficiency caused by HIV creates a situation
in which normally non-pathogenic organisms can cause
disease. Rather, the direct or indirect interplay between
pathogens in individuals with co-infection is presumed
to alter the normal progression of the disease seen in
individuals with a mono-infection. In the study by Qu et
al., individuals who had progressed to AIDS (as deter-
mined by CD4 and CD8 counts) were included in the
cohort to show a correlation between HIV, HCV and
IP-10 levels. It will be important in future experiments
to exclude individuals with an immunodeficiency as this
confounds the interpretation of the effect of HIV infec-
tion on HCV viral load and IP-10 levels in those indivi-
duals. The low CD4 counts are likely responsible for
some increase in HCV replication and, perhaps, the IP-
10 levels reported. Still, the finding that upregulation of
IP-10 expression by HIV tat can enhance the replication
of HCV illuminates IP-10 and HIV tat as targets for
therapeutic intervention in individuals co-infected with
HIV and HCV.
Conclusions
The work presented by Qu et al. advances our under-
standing of the relationship between HIV and HCV in
individuals with a co-infection, an area that is extremely
important yet poorly understood. These findings have
important implications for the rational design of thera-
peutic intervention to treat or prevent HCV liver disease
in both individuals with HIV and HCV co-infection as
well as those with an HCV mono-infection.
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